Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
4.770
-0.110 (-2.25%)
At close: May 13, 2026, 4:00 PM EDT
4.850
+0.080 (1.68%)
After-hours: May 13, 2026, 7:39 PM EDT

Intensity Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5.315.196.093.532.422.16
Research & Development
5.796.7910.54.795.135.86
Total Operating Expenses
11.111.9716.598.327.558.01
Operating Income
-11.1-11.97-16.59-8.32-7.55-8.01
Interest Income
0.260.180.310.3200
Interest Expense
----0.31-0.08-
Other Non-Operating Income (Expense)
0.150.190-2.240.050.12
Total Non-Operating Income (Expense)
0.410.370.32-2.22-0.030.12
Pretax Income
-10.69-11.61-16.27-10.54-7.58-7.9
Net Income
-10.69-11.61-16.27-10.54-7.58-7.9
Net Income Attributable to Preferred Dividends
---1.32--
Net Income to Common
-10.69-11.61-16.27-10.54-7.58-7.9
Shares Outstanding (Basic)
211000
Shares Outstanding (Diluted)
211000
Shares Change (YoY)
221.42%143.83%61.40%152.67%-0.02%
EPS (Basic)
-6.02-8.56-29.24-34.50-55.50-58.00
EPS (Diluted)
-6.02-8.56-29.24-34.50-55.50-58.00
Shares Outstanding
2.542.520.60.550.140.14
Free Cash Flow
-9.07-9.23-15.22-7.21-5.48-6.83
Free Cash Flow Per Share
-4.94-6.81-27.36-20.91-40.15-50.05
EBITDA
-11.08-11.95-16.56-8.17-7.37-7.84
EBIT
-11.1-11.97-16.59-8.32-7.55-8.01
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q